SynthesisTropical medicine & international health : TM & IH2026
Epidemiology of Monoclonal Gammopathies in Sub-Saharan Africa: A Systematic Review and Meta-Analysis of MGUS and Multiple Myeloma.
Synthesis in Tropical medicine & international health : TM & IH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) are reported to occur more frequently in Black populations, particularly African Americans. However, despite Sub-Saharan Africa (SSA) being home to the largest Black population globally, epidemiological data on MGUS and MM in the region remain scarce.
methodsWe conducted a systematic review and meta-analysis of published studies from SSA to estimate the pooled prevalence of MGUS and MM, regional variations, survival outcomes and key clinical complications, including HIV-associated MM, renal failure, anaemia and hypercalcaemia.
resultsForty-five studies were included in this systematic review and meta-analysis, with eight on MGUS and 37 on MM. The pooled prevalence of MGUS in SSA was 3.1% (95% CI: 0.8%-12.0%), while MM prevalence was 7.8% (95% CI: 5.6%-10.4%). MM burden was highest in Central Africa and lowest in West Africa, whereas MGUS prevalence peaked in Southern Africa. The pooled mean survival for MM was 34.7 months; 1-year and 5-year overall survival rates were 46.0% and 20.7%, respectively. HIV significantly modified MM outcomes: the pooled prevalence of MM among people living with HIV was 7.2% (95% CI: 1.9%-24.2%), and mean survival was markedly shorter in HIV-positive patients (9.9 months) compared with HIV-negative patients (36.7 months). Renal failure was highly prevalent, affecting 30.1% (95% CI: 23.5%-37.6%) of MM patients at diagnosis.
conclusionMM and MGUS impose a substantial and under-recognised burden in SSA, with poorer survival outcomes compared with global averages. The high rates of delayed presentation, limited diagnostic capacity, absence of routine plasma cell disorder screening and restricted access to modern therapies likely contribute to the disparities observed. Strengthening diagnostic infrastructure and improving early detection and treatment pathways are urgently needed to advance equity in myeloma care across SSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.